AU469986B2 - Sulfobenzylpenicillin salts - Google Patents

Sulfobenzylpenicillin salts

Info

Publication number
AU469986B2
AU469986B2 AU57600/73A AU5760073A AU469986B2 AU 469986 B2 AU469986 B2 AU 469986B2 AU 57600/73 A AU57600/73 A AU 57600/73A AU 5760073 A AU5760073 A AU 5760073A AU 469986 B2 AU469986 B2 AU 469986B2
Authority
AU
Australia
Prior art keywords
sulfobenzylpenicillin
salts
sulfobenzylpenicillin salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU57600/73A
Other languages
English (en)
Other versions
AU5760073A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU5760073A publication Critical patent/AU5760073A/en
Application granted granted Critical
Publication of AU469986B2 publication Critical patent/AU469986B2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU57600/73A 1972-07-01 1973-07-02 Sulfobenzylpenicillin salts Expired AU469986B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6630172A JPS5512435B2 (enExample) 1972-07-01 1972-07-01
JPJP66301/72 1972-07-01

Publications (2)

Publication Number Publication Date
AU5760073A AU5760073A (en) 1975-01-09
AU469986B2 true AU469986B2 (en) 1976-02-26

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57600/73A Expired AU469986B2 (en) 1972-07-01 1973-07-02 Sulfobenzylpenicillin salts

Country Status (15)

Country Link
US (1) US3925357A (enExample)
JP (1) JPS5512435B2 (enExample)
AT (1) AT325206B (enExample)
AU (1) AU469986B2 (enExample)
BE (1) BE801588A (enExample)
CA (1) CA996548A (enExample)
CH (1) CH573435A5 (enExample)
CS (1) CS168036B2 (enExample)
DE (1) DE2332840A1 (enExample)
FR (1) FR2190414B1 (enExample)
GB (1) GB1386566A (enExample)
HU (1) HU166029B (enExample)
NL (1) NL7308048A (enExample)
PL (1) PL92969B1 (enExample)
SE (1) SE402916B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (enExample) * 1978-07-29 1980-02-13
EP1368349B1 (de) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (enExample) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
BE801588A (fr) 1973-12-28
JPS5512435B2 (enExample) 1980-04-02
HU166029B (enExample) 1974-12-28
FR2190414B1 (enExample) 1976-07-02
AT325206B (de) 1975-10-10
CH573435A5 (enExample) 1976-03-15
CA996548A (en) 1976-09-07
GB1386566A (en) 1975-03-12
US3925357A (en) 1975-12-09
AU5760073A (en) 1975-01-09
JPS4925121A (enExample) 1974-03-06
SE402916B (sv) 1978-07-24
NL7308048A (enExample) 1974-01-03
DE2332840A1 (de) 1974-01-17
PL92969B1 (enExample) 1977-04-30
CS168036B2 (enExample) 1976-05-28
FR2190414A1 (enExample) 1974-02-01

Similar Documents

Publication Publication Date Title
AU469986B2 (en) Sulfobenzylpenicillin salts
AU454372B2 (en) Childsafe actuator-overcap
AU470375B2 (en) Substituted w-pentanorprostaglandins
AU469305B2 (en) Deipenylyl-alkanoylaminopyridine
AU5996573A (en) Pyridinium salts
CA980352A (en) Substituted aminohalopyridines
CA950831A (en) Biocidal salts
CA995666A (en) 1-amino-pyridinium salts
AU5709473A (en) S-substituted-2-thiodenosines
CA1018201A (en) Roller-lock
AU470359B2 (en) Sulphamoylphenyl-imidazolidinones
CA991638A (en) Substituted 3-cyanobenzenesulfonamides
CA1010049A (en) N-acyl-o-hydrocarbylphosphoroamidothioate salts
AU472956B2 (en) Substituted benzodioxoles
CA995680A (en) Substituted 2-benzoyloxazolidines
AU467526B2 (en) Pyronorifamycins
CA907019A (en) N-tritylimidazolium salts
CA913109A (en) Thienyliodonium salts
CA893696A (en) Amcyclodin salts
AU491554B1 (en) Pyridinium salts
CA893722A (en) Substituted hydro-2-naphthalenones
CA905407A (en) Substituted 3-aminoindazoles
CA904319A (en) Substituted benzthiazole-n-oxides
CA893124A (en) Substituted 2-azabicycloalkanes
CA889877A (en) Substituted hydroxyphenyl-alkylamines